The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization
- 775 Downloads
Acriflavine, a fluorescent drug previously used for bacterial and trypanosomal infections, reduces hypoxia-inducible factor-1 (HIF-1) and HIF-2 transcriptional activity. In mice with oxygen-induced ischemic retinopathy, intraocular or intraperitoneal injections of acriflavine caused dose-dependent suppression of retinal neovascularization (NV) and significantly reduced expression of HIF-1-responsive genes. Intraocular injection of 100 ng caused inner retina fluorescence within 1 h that was seen throughout the entire retina between 1 and 5 days, and at 7 days after injection, strongly suppressed choroidal NV at Bruch’s membrane rupture sites. After suprachoroidal injection of 300 ng in rats, there was retinal fluorescence in the quadrant of the injection at 1 h that spread throughout the entire retina and choroid by 1 day, was detectable for 5 days, and dramatically reduced choroidal NV 14 days after rupture of Bruch’s membrane. After topical administration of acriflavine in mice, fluorescence was seen in the retina and retinal pigmented epithelium within 5 min and was detectable for 6–12 h. Administration of 0.5% drops to the cornea twice a day significantly reduced choroidal NV in mice. Electroretinographic b-wave amplitudes were normal 7 days after intravitreous injection of 100 ng of acriflavine in mice, showed mild threshold reductions at highest stimulus intensities after injection of 250 ng, and more extensive changes after injection of 500 ng. These data provide additional evidence for an important role for HIF-1 in retinal and choroidal NV and suggest that acriflavine can target HIF-1 through a variety of modes of administration and has good potential to provide a novel therapy for retinal and choroidal vascular diseases.
Acriflavine, an inhibitor of HIF-1, suppresses retinal and choroidal neovascularization.
HIF-1 plays a critical role in ocular neovascularization.
Acriflavine’s fluorescence provides a mean to track its entry and exit from the retina.
Acriflavine has therapeutic potential for the treatment of ocular neovascularization.
KeywordsAge-related macular degeneration Diabetic retinopathy Ischemia Suprachoroidal injection Vascular endothelial growth factor
This study is supported by EY012609 from the National Eye Institute.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Klein R, Klein B (1995) Vision disorders in diabetes. In: Group NDD (ed) Diabetes in America National Institutes of Health. Washington, D.C., pp. 293–330Google Scholar
- 4.Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL (2003) Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93:1074–1081CrossRefPubMedGoogle Scholar
- 5.Vinores SA, Xiao WH, Aslam S, Shen J, Oshima Y, Nambu H, Liu H, Carmeliet P, Campochiaro PA (2006) Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 206:749–758CrossRefPubMedGoogle Scholar
- 15.Brown DM, Campochiaro PA, Singh RP, Gray S, Rundle AC, Li Z, Rubio RG, Murahashi WY, Group CS (2010) Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion:6-month results of the phase III CRUISE study. Ophthalmology 117:1124–1133CrossRefPubMedGoogle Scholar
- 17.Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168:2036–2053CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Campochiaro PA, Sophie R, Tolentino M, Miller DM, Browning D, Boyer DS, Heier JS, Gambino L, Withers B, Brigell M et al (2015) Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology 122:545–554CrossRefPubMedGoogle Scholar
- 26.Campochiaro PA, Khanani A, Singer M, Patel S, Boyer D, Dugel P, Kherani S, Withers B, Gambino L, Peters K et al (2016) Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression. Ophthalmology 123:1722–1730CrossRefPubMedGoogle Scholar
- 36.Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LEH (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 92:10457–10461CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Assinder EW (1936) Acriflavine as a urinary antiseptic. Lancet 227Google Scholar
- 46.Broekgaarden M, Weijer R, Krekorian M, van den IJssel B, Kos M, Alles LK, van Wijk AC, Hazai E, van Gulik TM, Heger M (2016) Inhibition of hypoxia-inducible factor 1 with acriflavine sensitizes hypoxic tumor cells to photodynamic therapy with zinc phthalocyanine-encapsulating cationic liposomes. Nano Res 9:1639–1662CrossRefGoogle Scholar